FDA approves Flexion's drug for knee pain: 3 things to know

Flexion Therapeutics on Friday earned Food and Drug Administration approval for Zilretta, an extended-release treatment for osteoarthritis knee pain.

Here are three things to know.

1. Zilretta is administered as an intra-articular injection.

2. The non-opioid drug is intended to provide pain relief for patients with moderate to severe OA knee pain over a 12-week period.

3. Flexion expects Zilretta to hit the market by the end of the month.

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars